CAI Revenue Flow
Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.
- 2026-06-30: Revenue $263.71M; Research and development $32.36M; Income tax $23.00K; Net income -$637.00K.
- 2026-03-31: Revenue $216.17M; Research and development $31.32M; Income tax -$134.00K; Net income -$510.00K.
- 2025-12-31: Revenue $292.89M*; Research and development $31.84M*; Income tax $0.00*; Net income $81.96M*.
- 2025-09-30: Revenue $216.83M; Research and development $21.62M; Income tax $0.00; Net income $24.32M.
Product or service
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Geography
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Type Of Arrangement
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.
Historical revenue and expense breakdown
Revenue and expense 3 month
| Period end | Revenue | Research and development | Income tax | Net income |
|---|---|---|---|---|
| 2026-06-30 | $263.71M | $32.36M | $23.00K | -$637.00K |
| 2026-03-31 | $216.17M | $31.32M | -$134.00K | -$510.00K |
| 2025-12-31 | $292.89M* | $31.84M* | $0.00* | $81.96M* |
| 2025-09-30 | $216.83M | $21.62M | $0.00 | $24.32M |
| 2025-06-30 | $181.40M | $25.05M | $0.00 | -$71.79M |
| 2025-03-31 | $120.92M | $23.07M | $0.00 | -$102.58M |
| 2024-09-30 | $101.62M | $27.64M | $0.00 | -$67.73M |
| 2024-06-30 | $100.05M | $24.79M | $0.00 | -$66.19M |
Revenue and expense 6 month
| Period end | Revenue | Research and development | Income tax | Net income |
|---|---|---|---|---|
| 2026-06-30 | $479.89M | $63.67M | -$111.00K | -$1.15M |
| 2025-06-30 | $302.31M | $48.11M | $0.00 | -$174.37M |
| 2024-06-30 | $180.73M | $59.16M | $0.00 | -$177.21M |
Revenue and expense 9 month
| Period end | Revenue | Research and development | Income tax | Net income |
|---|---|---|---|---|
| 2025-09-30 | $519.15M | $69.74M | $0.00 | -$150.04M |
| 2024-09-30 | $282.35M | $86.81M | $0.00 | -$244.94M |
Revenue and expense 12 month
| Period end | Revenue | Research and development | Income tax | Net income |
|---|---|---|---|---|
| 2025-12-31 | $812.03M | $101.58M | $0.00 | -$68.09M |
| 2024-12-31 | $412.26M | $113.92M | $0.00 | -$281.89M |
| 2023-12-31 | $306.13M | $116.88M | $0.00 | -$341.42M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |